Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevan...Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevant case-control studies were enrolled in the meta-analysis. We applied Rev Man 4.2 software to pool raw data and test studies' heterogeneity and to calculate the incorporated odds ratio (OR) and 95% confidence interval (95% CI). Results: Our data showed that the OR for the Gln allele of the Arg399Gln polymorphism, compared with the Arg allele, was 1.35 (95% CI, 1.16-1.57; P〈0.0001) for childhood ALL patients. Similarly, the homozygous genotype Gln/Gln and heterozygous genotype Arg/Gln both significantly increased the risk of childhood ALL compared with the wild genotype Arg/Arg (OR =1.58; 95% CI, 1.13-2.21; P=0.008; OR =1.51; 95% CI, 1.21-1.87; P=0.0002). The dominant model of Arg399Gln was associated with childhood ALL risk (OR =1.54; 95% CI, 1.25-1.89; P〈0.0001). The ethnic subgroup analysis demonstrated that the Gln allele in all five ethnic groups was prone to be a risk factor for childhood ALL just with different degrees of correlation while Arg194Trp SNP showed a protective or risk factor or irrelevant thing in different races. Conclusions: XRCC1 399 polymorphism may increase the risk of childhood ALL. Different ethnic groups with some gene polymorphism have different disease risks.展开更多
Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCCI) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. M...Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCCI) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. Methods: Immunohistochemistry (IHC) was used to evaluate XRCCI protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Among 612 patients staged II/III in our study, 182 (29.74%) were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS (P=0.347) or DFS (P=0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS (P=0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P=0.049). Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS (P〈0.05). Though XRCCI plays an important role in DNA repair pathways, no significant relationship is found in XRCCI expression and OS among gastric cancer in our study. Conclusions: XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.展开更多
目的探讨XRCC1基因Arg194Trp、Arg399Gln单核苷酸多态性(SNP)与外生型宫颈鳞状细胞癌放疗敏感性的关系。方法选择经组织病理学确诊的外生型宫颈鳞状细胞癌患者73例。其中临床分期Ⅰ期4例,Ⅱ期36例,Ⅲ期30例,Ⅳ期3例。肿瘤直径≤4 cm 30...目的探讨XRCC1基因Arg194Trp、Arg399Gln单核苷酸多态性(SNP)与外生型宫颈鳞状细胞癌放疗敏感性的关系。方法选择经组织病理学确诊的外生型宫颈鳞状细胞癌患者73例。其中临床分期Ⅰ期4例,Ⅱ期36例,Ⅲ期30例,Ⅳ期3例。肿瘤直径≤4 cm 30例,肿瘤直径>4 cm 43例;A点剂量≤80 Gy者36例,A点剂量>80 Gy者37例。近期疗效为完全缓解者(CR组)47例,部分缓解者(PR组)26例。采用错配扩增聚合酶链式反应检测患者血液标本的XRCC1 Arg194Trp、Arg399Gln SNP的基因型频率分布,分析其与宫颈癌放疗敏感性的关系。结果 XRCC1基因Arg194Trp分型中,携带Arg/Arg、Arg/Trp、TrP/Trp分别有31例(42.5%)、37例(50.7%)、5例(6.8%);Arg399Gln分型中,携带Arg/Arg、Arg/Gln、Gln/Gln分别有26例(35.6%)、39例(53.4%)、8例(11.0%)。CR组与PR组Arg194Trp、Arg399Gln基因型分布差异均无统计学意义。影响放疗敏感性的多因素Logistic回归分析结果显示,临床分期晚为PR的危险因素。结论 XRCC1基因Arg194TrpSNP、Arg399Gln SNP与外生型宫颈鳞状细胞癌放疗敏感性无相关性。临床分期越晚放疗敏感性越差。展开更多
目的探讨原发性肝癌组织和正常肝脏组织的DNA损伤修复基因XRCC1启动子甲基化状态,分析其与肝癌易感性的关系及对患者预后的影响。方法甲基化特异性PCR检测手术切除的肝癌组织78例及正常肝组织78例的XRCC1基因甲基化情况,并随访3年以上...目的探讨原发性肝癌组织和正常肝脏组织的DNA损伤修复基因XRCC1启动子甲基化状态,分析其与肝癌易感性的关系及对患者预后的影响。方法甲基化特异性PCR检测手术切除的肝癌组织78例及正常肝组织78例的XRCC1基因甲基化情况,并随访3年以上。结果肝癌组的XRCC1启动子甲基化率远高于对照组(P<0.05),肝癌组发生XRCC1启动子甲基化的危险是对照组的13倍(4.089 vs 41.332);XRCC1启动子甲基化的个体发生肝癌的危险是非甲基化的10.36倍(3.423 vs 31.354)(P<0.05);XRCC1启动子甲基化可致肝癌患者无进展期生存率和总体生存率降低(P<0.05)。结论 DNA损伤修复基因XRCC1启动子甲基化在肝癌发生和发展的过程中起着重要作用,并对肝癌患者较差的预后具有提示作用。展开更多
Objective: Hepatocellular carcinoma (HCC) is a complex disease which associates with both environmental and genetic factors. The purpose of this study was to investigate whether the genetic polymorphisms of UDP-glu...Objective: Hepatocellular carcinoma (HCC) is a complex disease which associates with both environmental and genetic factors. The purpose of this study was to investigate whether the genetic polymorphisms of UDP-glucuronosyltransferase(UGT1A7), an important phase II biotransformation enzyme, and X-ray repair cross-complementing group 1(XRCC1), a pivotal DNA-repair gene, were related to the risk of HCC in Northeast China. Methods: One hundred and thirty six HCC patients and one hundred and thirty six frequency-matched controls were included in this hospital-based case-control study. Genotypes of UGT1A7 and XRCC1 were determined using allele-specific polymerase chain reaction (AS-PCR) and PCR-restriction fragment length polymorphism (RFLP), and for which the odds ratio (OR) with 95% confidence interval (95% CI) were calculated. Results: The proportion of UGT1A7 low enzymatic allele (*2 or *3) was higher in HCC patients than those in controls. The UGT1A7*1/*2 and *3/*3 genotypes were associated with higher HCC risk (OR=2.09, 95%CI: 1.10-3.97; OR=5.67, 95%CI: 1.76-18.30, respectively). The XRCC1 codon 399 Arg/Gln genotype could also elevate HCC risk (OR=2.16, 95% CI 1.29-3.61). In addition to polymorphisms of UGT1A7 and XRCC1, multivariate logistic regression analysis demonstrated that other significant independent factors associated with HCC were HBV infection (OR=68.07, 95%CI: 28.03-165.26), HCV infection (OR=30.97, 95%CI: 8.06-118.94) and family history of HCC (OR=10.62, 95%CI: 2.22-50.77). Conclusion: The study shows that the polymorphisms of UGT1A7 and XRCC1 are associated with HCC risk. Determination of the polymorphisms of UGT1A7 and XRCC1 may provide an important clue to preventive measure against HCC.展开更多
Objective:To assess the association between X-ray repair cross-complementating group 1 (XRCC1) polymorphisms and pancreatic cancer.Methods:We searched MEDLINE,Web of Science and HuGE Navigator at June 2010,and the...Objective:To assess the association between X-ray repair cross-complementating group 1 (XRCC1) polymorphisms and pancreatic cancer.Methods:We searched MEDLINE,Web of Science and HuGE Navigator at June 2010,and then quantitatively summarized associations of the XRCC1 polymorphisms with pancreatic cancer risk using meta-analysis.Results:Four studies with 1343 cases and 2302 controls were included.Our analysis found:at codon 194,the Trp allele did not decrease pancreatic cancer risk (Arg/Arg versus Trp/Trp:OR=0.97;95% CI:0.48-1.96;P=0.97;Arg/Arg versus Arg/Trp:OR=0.89;95% CI:0.70-1.13;P=0.55;Arg/Trp versus Trp/Trp:OR=1.06;95% CI:0.52-2.16;P=0.90);at codon 280,only a study showed a nonsignificant association between single nucleotide polymorphism with pancreatic cancer risk;at codon 399,the Gln allele also showed no signi?cant effect on pancreatic cancer compared to Arg allele (Arg/Arg versus Gln/Gln:OR=0.94;95% CI:0.74-1.18;Arg/Arg versus Arg/Gln:OR=0.97;95% CI:0.83-1.13;Arg/Gln versus Gln/Gln:OR=0.97;95% CI:0.77-1.22).The shape of the funnel plot and the Egger's test did not detect any publication bias.Conclusion:There is no evidence that XRCC1 polymorphisms (Arg194Trp,Arg280His,and Arg399Gln) are associated with pancreatic cancer risk.展开更多
文摘Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevant case-control studies were enrolled in the meta-analysis. We applied Rev Man 4.2 software to pool raw data and test studies' heterogeneity and to calculate the incorporated odds ratio (OR) and 95% confidence interval (95% CI). Results: Our data showed that the OR for the Gln allele of the Arg399Gln polymorphism, compared with the Arg allele, was 1.35 (95% CI, 1.16-1.57; P〈0.0001) for childhood ALL patients. Similarly, the homozygous genotype Gln/Gln and heterozygous genotype Arg/Gln both significantly increased the risk of childhood ALL compared with the wild genotype Arg/Arg (OR =1.58; 95% CI, 1.13-2.21; P=0.008; OR =1.51; 95% CI, 1.21-1.87; P=0.0002). The dominant model of Arg399Gln was associated with childhood ALL risk (OR =1.54; 95% CI, 1.25-1.89; P〈0.0001). The ethnic subgroup analysis demonstrated that the Gln allele in all five ethnic groups was prone to be a risk factor for childhood ALL just with different degrees of correlation while Arg194Trp SNP showed a protective or risk factor or irrelevant thing in different races. Conclusions: XRCC1 399 polymorphism may increase the risk of childhood ALL. Different ethnic groups with some gene polymorphism have different disease risks.
基金supported by the National Natural Science Foundation of China(No.81100274,81001428)a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions(PAPD)
文摘Objective: The aim of this study is to identify the prognostic significance of X-ray cross-complementing gene 1 (XRCCI) in patients with gastric cancer undergoing surgery and platinum-based adjuvant chemotherapy. Methods: Immunohistochemistry (IHC) was used to evaluate XRCCI protein expression profiles on surgical specimens of 612 gastric cancer patients. The relationship between XRCC1 expression and existing prognostic factors, platinum-based adjuvant chemotherapy, disease-free survival (DFS) and overall survival (OS) were analyzed. Results: Among 612 patients staged II/III in our study, 182 (29.74%) were evaluated as XRCC1 IHC positive. XRCC1 expression was not significantly related to OS (P=0.347) or DFS (P=0.297). Compared with surgery only, platinum-based adjuvant chemotherapy significantly improved the OS (P=0.031). And the patients with negative XRCC1 expression benefited more from platinum-based adjuvant chemotherapy (P=0.049). Multivariate analysis demonstrated that tumor size, T category, N category, vascular or nerve invasion and platinum-based chemotherapy were good prognostic factors for OS (P〈0.05). Though XRCCI plays an important role in DNA repair pathways, no significant relationship is found in XRCCI expression and OS among gastric cancer in our study. Conclusions: XRCC1 might be an alternative prognostic marker for the patients of gastric cancer after radical resection. The patients with negative XRCC1 expression can benefit more from platinum-based adjuvant chemotherapy.
文摘目的探讨原发性肝癌组织和正常肝脏组织的DNA损伤修复基因XRCC1启动子甲基化状态,分析其与肝癌易感性的关系及对患者预后的影响。方法甲基化特异性PCR检测手术切除的肝癌组织78例及正常肝组织78例的XRCC1基因甲基化情况,并随访3年以上。结果肝癌组的XRCC1启动子甲基化率远高于对照组(P<0.05),肝癌组发生XRCC1启动子甲基化的危险是对照组的13倍(4.089 vs 41.332);XRCC1启动子甲基化的个体发生肝癌的危险是非甲基化的10.36倍(3.423 vs 31.354)(P<0.05);XRCC1启动子甲基化可致肝癌患者无进展期生存率和总体生存率降低(P<0.05)。结论 DNA损伤修复基因XRCC1启动子甲基化在肝癌发生和发展的过程中起着重要作用,并对肝癌患者较差的预后具有提示作用。
基金supported by the grant from Department of Education of Liaoning Province, China (No. 2008S232)
文摘Objective: Hepatocellular carcinoma (HCC) is a complex disease which associates with both environmental and genetic factors. The purpose of this study was to investigate whether the genetic polymorphisms of UDP-glucuronosyltransferase(UGT1A7), an important phase II biotransformation enzyme, and X-ray repair cross-complementing group 1(XRCC1), a pivotal DNA-repair gene, were related to the risk of HCC in Northeast China. Methods: One hundred and thirty six HCC patients and one hundred and thirty six frequency-matched controls were included in this hospital-based case-control study. Genotypes of UGT1A7 and XRCC1 were determined using allele-specific polymerase chain reaction (AS-PCR) and PCR-restriction fragment length polymorphism (RFLP), and for which the odds ratio (OR) with 95% confidence interval (95% CI) were calculated. Results: The proportion of UGT1A7 low enzymatic allele (*2 or *3) was higher in HCC patients than those in controls. The UGT1A7*1/*2 and *3/*3 genotypes were associated with higher HCC risk (OR=2.09, 95%CI: 1.10-3.97; OR=5.67, 95%CI: 1.76-18.30, respectively). The XRCC1 codon 399 Arg/Gln genotype could also elevate HCC risk (OR=2.16, 95% CI 1.29-3.61). In addition to polymorphisms of UGT1A7 and XRCC1, multivariate logistic regression analysis demonstrated that other significant independent factors associated with HCC were HBV infection (OR=68.07, 95%CI: 28.03-165.26), HCV infection (OR=30.97, 95%CI: 8.06-118.94) and family history of HCC (OR=10.62, 95%CI: 2.22-50.77). Conclusion: The study shows that the polymorphisms of UGT1A7 and XRCC1 are associated with HCC risk. Determination of the polymorphisms of UGT1A7 and XRCC1 may provide an important clue to preventive measure against HCC.
文摘Objective:To assess the association between X-ray repair cross-complementating group 1 (XRCC1) polymorphisms and pancreatic cancer.Methods:We searched MEDLINE,Web of Science and HuGE Navigator at June 2010,and then quantitatively summarized associations of the XRCC1 polymorphisms with pancreatic cancer risk using meta-analysis.Results:Four studies with 1343 cases and 2302 controls were included.Our analysis found:at codon 194,the Trp allele did not decrease pancreatic cancer risk (Arg/Arg versus Trp/Trp:OR=0.97;95% CI:0.48-1.96;P=0.97;Arg/Arg versus Arg/Trp:OR=0.89;95% CI:0.70-1.13;P=0.55;Arg/Trp versus Trp/Trp:OR=1.06;95% CI:0.52-2.16;P=0.90);at codon 280,only a study showed a nonsignificant association between single nucleotide polymorphism with pancreatic cancer risk;at codon 399,the Gln allele also showed no signi?cant effect on pancreatic cancer compared to Arg allele (Arg/Arg versus Gln/Gln:OR=0.94;95% CI:0.74-1.18;Arg/Arg versus Arg/Gln:OR=0.97;95% CI:0.83-1.13;Arg/Gln versus Gln/Gln:OR=0.97;95% CI:0.77-1.22).The shape of the funnel plot and the Egger's test did not detect any publication bias.Conclusion:There is no evidence that XRCC1 polymorphisms (Arg194Trp,Arg280His,and Arg399Gln) are associated with pancreatic cancer risk.